As M2 macrophages are the most prevalent immune cell type in meningiomas, Yeung et al. have targeted with a specific monoclonal antibody the colony-stimulating factor 1 (CSF1) and CFS1 receptor (CSF1R) expressed in myeloid cells, reporting a significant reduction in tumor growth in a murine meningioma model. This evidence concerns the gene CSF1 and meningioma.